Table 1

Details of included studies

YearDesignStudy durationACS presentationsTerritory studiedFFR cut-offVasodilatorsMACE definitionsFollow-up period
FAME2011Prospective, multicentre, randomised control trial01/2006-09/2007NSTEACSCulprit and non-culprit0.8IV adenosineAll-cause mortality, MI, revascularisation24 months
PRIME-FFR2017Prospective, international multicentre registryR3F: 10/2008-06/2010; POST-IT: 03/2012-11/2013NSTEACSCulprit and non-culprit0.8IC or IV adenosineAll-cause mortality, MI, revascularisation12 months
Potvin et al 10 2006Not specified04/2002-09/2004ACS (not within 24 hours of STEMI)Culprit and non-culprit0.75IC adenosine or nitroprussideCV Death, MI, revascularisation11+/-6 months
Fischer et al 9 2006Single-centre, observational4/2002-9/2004ACSCulprit and non-culprit>0.75NRAll-cause mortality, MI, TVR12 months
Mehta et al 12 2015Retrospective, single-centre, observational10/2002-07/2012ACSCulprit and non-culprit2002–2008:≥0.75; 2008–2012:>0.80IC adenosine (812 lesions), IV (four lesions)CV Death, MI, TLR4.5+/-2.1 years
Hakeem et al 132016Retrospective, single-centre, observational, propensity matched3/2009-10/2014NSTEACSCulprit and non-culprit>0.75IC or IV adenosineCV death, MI, TLR3.4+/-1.6 years
SWEDE HEART2017Prospective, multicentre, randomised, blinded trial1/2014-12/2015NSTEACSNon-culprit>0.80IC or IV hyperemic agentsAll-cause mortality, MI, TVR12 months
DEFINE FLAIR2017Multicentre, randomised, controlled, open-label trial5/2014-10/2015NSTEACSNon-culprit>0.80IC or IV adenosineAll-cause mortality, MI, TVR12 months
Lee et al 18 2017Multicentre, prospective, registry4-Centres: 2003–2011; FFR FRIENDS 2011–2014NSTEACSNon-culprit>0.80IC or IV adenosineCV death, target vessel MI, revascularisation722 days

  • ACS, acute coronary syndrome; CV, cardiovascular; FFR, fractional flow reserve; IC, intracoronary; MACE, major adverse cardiovascular events; MI, myocardial infarction; NR, not reported; NSTEACS, non-ST elevation acute coronary syndrome; STEMI, ST elevation myocardial infarction; TLR, target lesion revascularisation.